Riskpilot← Back to searchSign inGet full accessBio-Cide Scandinavia AB
ABActiveOrg 5565646238VallgatanWholesale of pharmaceutical and medical goods · NACE 4646Est. 19980 employees
Revenue 2025
SEK 60K
EBITDA margin
-0.6%
Equity ratio
84.5%
Financial strength
Net profit 2025
SEK -3K
-140% vs 2024
| Revenue | SEK 60K | — |
| EBITDA | SEK -376 | — |
| Net profit | SEK -3K | -140% |
| Total assets | SEK 281K | -5% |
| Equity | SEK 237K | -8% |
| Employees | 0 | — |
Legal name
Bio-Cide Scandinavia AB
Org number
5565646238
Legal form
Aktiebolag
NACE code
4646 · Wholesale of pharmaceutical and medical goods
Founded
29 december 1998
Share capital
SEK 100 000
Employees
0
VAT registered
Yes
Audit selected
No
Last report
2025-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen Firman tecknas var för sig av ledamoten suppleanten
Company purpose
Bolaget skall bedriva försäljning i Europa avseende kemikalier företrädesvis genom direktförsäljning eller agentupplåtelse ävensom idka därmed förenlig verksamhet.
Address
Vallgatan
Phone
+4687059905
Email
iris3@telia.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 83 | 62 | 62 | 0 | 60 |
| Staff expenses | — | — | — | — | — |
| EBITDA | 27 | 1 | −25 | — | −0 |
| Depreciation & amort. | −3 | −4 | −3 | −1 | −2 |
| EBIT | 24 | −3 | −28 | −1 | −3 |
| Net financials | — | 110 | — | — | −0 |
| Profit before tax | 24 | −113 | −28 | −1 | −3 |
| Tax | −0 | −0 | −0 | — | — |
| Net profit | 24 | −113 | −28 | −1 | −3 |
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total assets | 433 | 339 | 297 | 296 | 281 |
| Equity | 399 | 287 | 258 | 257 | 237 |
| Long-term debt | 0 | 0 | 34 | 34 | 0 |
| Short-term debt | 34 | 52 | 5 | 5 | 44 |
| Total debt | 34 | 52 | 39 | 39 | 44 |
EBITDA margin
-0.6%
This company
15.8%
Market median
-104% vs market
20212025
Equity ratio
84.5%
This company
38.2%
Market median
+121% vs market
20212025
Return on equity
-1.2%
This company
18.4%
Market median
-107% vs market
20212025
Net profit margin
-4.6%
This company
8.1%
Market median
-157% vs market
20212025
Asset turnover
0.21×
This company
1.12×
Market median
-81% vs market
20212025
Debt / equity
0.18×
This company
0.62×
Market median
+71% vs market
20212025
- Annual report 2025Filed via Bolagsverket / SCB · Period 2025-01-01 – 2025-12-31
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
No data on file.
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
| Board of Directors | 2022 | |
| Deputy Board Member | 2022 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Bio-Cide Scandinavia AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Hans Magnus Nyström | Board of Directors | 0 companies |
| Lars Christer Olsson | Deputy Board Member | 0 companies |